VeraDermics
New Haven
About VeraDermics
Veradermics is a dermatology-focused biopharmaceutical company that develops treatments for common skin and hair conditions. Its lead drug candidate, VDPHL01, is an extended-release oral minoxidil being tested in Phase 3 clinical trials for pattern hair loss in both women and men. The company also has pipeline programs targeting conditions such as common warts, molluscum contagiosum, and atopic dermatitis.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $260.7M
- Funding stage: Late Stage Venture
- Last round: Series C (Oct 2025)
- Website: veradermics.com
- Phone: [email protected]
Industries & Categories
Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/veradermics-55224 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.